Key Takeaways
- ACXP shares jumped more than 218% during the week following news of a clinical trial launch for ibezapolstat, its primary antibiotic candidate.
- Phase 2 results demonstrated a 96% cure rate for C. difficile infection (CDI), with no patients experiencing a recurrence after successful treatment.
- A 20-patient open-label pilot study targeting recurrent CDI patients is now underway, paving the way for a larger Phase 3 registration trial.
- Both U.S. and European health authorities have provided Acurx with a defined pathway to commence international Phase 3 clinical studies.
- The company’s 2025 fiscal year net loss decreased to $8.0 million from $14.1 million, while cash reserves rose to $7.6 million.
Acurx Pharmaceuticals (ACXP) delivered one of biotech’s most dramatic performances this year. Shares rocketed more than 218% across five trading sessions after the company revealed plans for a new clinical study evaluating ibezapolstat, its flagship antibiotic designed to treat C. difficile infections.
Acurx Pharmaceuticals, Inc., ACXP
The majority of gains materialized following Monday’s announcement outlining the Phase 3 strategy. By Friday’s opening bell, shares tacked on an additional 3.59% in pre-market activity after the company released its fourth-quarter financial results.
C. difficile infection, commonly abbreviated as CDI, is a bacterial condition affecting the gastrointestinal tract that frequently recurs. Patients who experience three or more episodes within a single year face limited therapeutic alternatives, and the likelihood of recurrence remains persistently high.
Phase 2 trial outcomes for ibezapolstat provided compelling evidence for investors. The compound achieved a 96% clinical cure rate among 26 participants suffering from acute CDI. Even more noteworthy — zero cured patients experienced a return of the infection throughout the observation window.
This dual capacity for both treatment and prevention is what Acurx considers ibezapolstat’s differentiating factor. Existing therapies typically address the active infection but fail to prevent subsequent recurrences.
The biotech company is now initiating a 20-participant open-label pilot study targeting individuals with multiply-recurrent CDI — specifically those who’ve experienced a minimum of three episodes over the preceding 12 months. Data from this pilot program will inform the structure and endpoints of the pivotal Phase 3 registration study.
Green Light From Regulators
Among the week’s most significant developments was confirmation that regulatory bodies in both the United States and Europe have provided Acurx with defined guidelines to initiate international Phase 3 clinical investigations. For a small-cap biotechnology company, this type of coordinated regulatory clarity eliminates substantial uncertainty.
The announcement also indicates that the company’s trial strategy extends beyond domestic borders — international expansion is integrated into the development plan from the outset.
In February 2026, Acurx secured additional patent protection for its Pol IIIC inhibitor compounds, extending exclusivity rights through December 2039. Should the drug achieve commercialization, this represents substantial intellectual property coverage.
Fourth Quarter Results: Improving Bottom Line
Financially, Acurx posted a Q4 2025 loss of $5.32 per share, representing a larger deficit than the $3.29 per-share loss recorded in Q4 2024. However, the annual perspective reveals progress.
Across the entire 2025 fiscal year, the net loss totaled $8.0 million versus $14.1 million during 2024 — representing a substantial improvement. Research and development expenditures declined to $0.3 million from $0.8 million, while general and administrative costs fell to $1.3 million from $2.0 million.
The company’s cash position also strengthened. Acurx concluded December 31, 2025 holding $7.6 million in cash and equivalents, compared to $3.7 million at the prior year-end. This provides a more stable foundation as the company advances its trial initiatives.
Currently, two Wall Street analysts maintain a Moderate Buy rating on ACXP, with a consensus 12-month price target of $17.50.
Following Friday morning’s earnings disclosure, shares were trading up 3.59% in pre-market hours on confirmation of the recurrent CDI trial commencement.
